Nov 17, 2022 / 09:45AM GMT
Dave Stanton - Jefferies LLC - Head of Healthcare Equity Research
Good afternoon, everyone. Welcome to another afternoon session of the Jefferies London Healthcare Conference. My name is Dave Stanton. I'm part of the Jefferies Australia healthcare research team. It's my absolute pleasure to be hosting Immunocore Holdings today, and Bahija Jallal, CEO of Immunocore Holdings and David Berman, Head of Research and Development is with us.
Bahija Jallal - Immunocore Holdings plc - CEO
Good morning and thank you for having us to talk about Immunocore today, it's our distinct pleasure to do so. Our mission is to harness -- this is our forward-looking statements. Our mission is to harness the power of the immune system to fight diseases with targeted, off-the-shelf, bispecific, soluble T cell receptor. And we believe that this platform can address unmet medical need in immuno-oncology and beyond.
And as a matter of fact, the last -- in January, we had the distinct pleasure of actually validating this platform with the approval of KIMMTRAK. That's the first and
Immunocore Holdings PLC at Jefferies London Healthcare Conference Transcript
Nov 17, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers